Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio Elkis

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 26, 2018
Meta-analyses of cavum septum pellucidum in mood disorders in comparison with healthy controls or schizophreniaGabriel H Beraldi, Kelly S Prado, Benedikt L Amann, et al.
Psychiatry Research|November 5, 2021
Which are the best evidence-based therapeutic options for clozapine and ECT resistant schizophrenia? A case-reportRodolfo Furlan Damiano, Belquiz S Avrichir, Débora L Melzer-Ribeiro, et al.
Comprehensive Psychiatry|August 18, 2009
Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidolAntonio R Sa, Ana G Hounie, Aline S Sampaio, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|April 1, 2008
[Brazilian Consensus on second-generation antipsychotics and metabolic disorders]Helio Elkis, Clarissa Gama, Henrique Suplicy, et al.
The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|November 15, 2021
Occupational Goal Intervention Method for the Management of Executive Dysfunction in People With Treatment-Resistant Schizophrenia: A Randomized Controlled TrialAdriana Vizzotto, Diego Celestino, Patricia Buchain, et al.
Biological Psychiatry|April 30, 2005
Obsessive-compulsive symptoms among patients with Sydenham choreaFernando R Asbahr, Marjorie A Garvey, Lisa A Snider, et al.
Schizophrenia Research|September 8, 2012
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/dayHerbert Y Meltzer, Helio Elkis, Kimberly Vanover, et al.
Schizophrenia Research|August 4, 2023
Clozapine safety monitoring and related research in psychiatry and neurology in South America: A scoping reviewTrino Baptista, Ana Serrano, Alirio Perez Lo Presti, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|October 22, 2013
Why we should use long-acting injectable antipsychotics more frequentlyJoão Paulo Maia-de-Oliveira, Rodrigo A Bressan, Helio Elkis, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|November 24, 2022
Negative dimension stability across clinical stages and sociodemographic characteristics in schizophreniaGabriela Koga, Bernardo Haguiara, Bruno Ortiz, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 26, 2018
Meta-analyses of cavum septum pellucidum in mood disorders in comparison with healthy controls or schizophreniaGabriel H Beraldi, Kelly S Prado, Benedikt L Amann, et al.
Psychiatry Research|November 5, 2021
Which are the best evidence-based therapeutic options for clozapine and ECT resistant schizophrenia? A case-reportRodolfo Furlan Damiano, Belquiz S Avrichir, Débora L Melzer-Ribeiro, et al.
Comprehensive Psychiatry|August 18, 2009
Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidolAntonio R Sa, Ana G Hounie, Aline S Sampaio, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|April 1, 2008
[Brazilian Consensus on second-generation antipsychotics and metabolic disorders]Helio Elkis, Clarissa Gama, Henrique Suplicy, et al.
The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|November 15, 2021
Occupational Goal Intervention Method for the Management of Executive Dysfunction in People With Treatment-Resistant Schizophrenia: A Randomized Controlled TrialAdriana Vizzotto, Diego Celestino, Patricia Buchain, et al.
Biological Psychiatry|April 30, 2005
Obsessive-compulsive symptoms among patients with Sydenham choreaFernando R Asbahr, Marjorie A Garvey, Lisa A Snider, et al.
Schizophrenia Research|September 8, 2012
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/dayHerbert Y Meltzer, Helio Elkis, Kimberly Vanover, et al.
Schizophrenia Research|August 4, 2023
Clozapine safety monitoring and related research in psychiatry and neurology in South America: A scoping reviewTrino Baptista, Ana Serrano, Alirio Perez Lo Presti, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|October 22, 2013
Why we should use long-acting injectable antipsychotics more frequentlyJoão Paulo Maia-de-Oliveira, Rodrigo A Bressan, Helio Elkis, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|November 24, 2022
Negative dimension stability across clinical stages and sociodemographic characteristics in schizophreniaGabriela Koga, Bernardo Haguiara, Bruno Ortiz, et al.
Pageof 7